Abstract:Colorectal cancer (CRC) is currently the third most common cancer with a high mortality rate. The underlying molecular mechanism of CRC, especially advanced CRC, remains poorly understood, resulting in few available therapeutic plans. To expand our knowledge of the molecular characteristics of advanced CRC and explore possible new therapeutic strategies, we herein conducted integrated proteomics and metabolomics analyses of 40 serum samples collected from 20 advanced CRC patients before and after treatment. The mass spectrometry-based proteomics analysis was performed under data-independent acquisition (DIA), and the metabolomics analysis was performed by ultra-performance liquid chromatography coupled with time-of-flight tandem mass spectrometry (UPLC-TOF-MS/MS). Trace elements including Mg, Zn, and Fe were measured by inductively coupled plasma spectrometry (ICP-MS) analysis. Four of the 20 patients had progressive disease (PD) after treatment, and clinical test results indicated that they all had impaired liver functions. In the proteomics analysis, 64 proteins were discovered to be significantly altered after treatment. These proteins were enriched in cancer-related pathways and pathways participating immune responses, such as MAPK signaling pathway and complement/coagulation cascades. In the metabolomics analysis, 128 metabolites were found to be significantly changed after treatment, and most of them are enriched in pathways associated with lipid metabolism. The cholesterol metabolism pathway was significantly enriched in both the proteomics and metabolomics pathway enrichment analyses. The concentrations of Mg in the serums of CRC patients were significantly lower than those in healthy individuals, which returned to the normal range after treatment. Correlation analysis linked key lipids, proteins, and Mg as immune modulators in the development of advanced CRC. The results of this study not only extended our knowledge on the molecular basis of advanced CRC but also provided potential novel therapeutic targets for CRC treatment.

Molecular Characterization of Advanced Colorectal Cancer Using Serum Proteomics and Metabolomics

Ultra-Performance Liquid Chromatography Coupled with Quadrupole Time-Of-Flight Mass Spectrometry-Based Metabolic Profiling of Human Serum Prior to and Following Radical Resection of Colorectal Carcinoma

Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS.

Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery.

Characterization of the Fatty Acid Metabolism in Colorectal Cancer to Guide Clinical Therapy

Comprehensive serum proteomics profiles and potential protein biomarkers for the early detection of advanced adenoma and colorectal cancer

Correlation Analysis Between Trace Elements and Colorectal Cancer Metabolism by Integrated Serum Proteome and Metabolome

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Advances in Epigenetic Biomarker Research in Colorectal Cancer.

Combination of GC-MS based metabolomics analysis with mouse xenograft models reveals a panel of dysregulated circulating metabolites and potential therapeutic targets for colorectal cancer

LC–MS-based serum metabolomics analysis for the screening and monitoring of colorectal cancer

An Integrated Proteomics and Metabolomics Approach for Defining Oncofetal Biomarkers in the Colorectal Cancer

Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry.

Metabonomics Identifies Serum Metabolite Markers of Colorectal Cancer

Metabolomic Comparison of Patients With Colorectal Cancer at Different Anticancer Treatment Stages

Applying Proteomics Integrated With Gene Microarray for Discovery of Colorectal Cancer Novel Biomarkers

Profiling the metabolic disorder and detection of colorectal cancer based on targeted amino acids metabolomics

Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers

Untargeted GC-MS-Based Metabolomics for Early Detection of Colorectal Cancer

Evaluation of the Diagnostic Value of Serum-Based Proteomics for Colorectal Cancer.

Lipid Profiling for Early Diagnosis and Progression of Colorectal Cancer Using Direct-Infusion Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometry.